ABSTRACT: Traumatic composite bone-muscle injuries, such as open fractures, often require multiple surgical interventions and still typically result in long-term disability. Clinically, a critical indicator of composite injury severity is vascular integrity; vascular damage alone is sufficient to assign an open fracture to the most severe category. Challenging bone injuries are often treated with bone morphogenetic protein 2 (BMP-2), an osteoinductive growth factor, delivered on collagen sponge. Previous studies in a composite defect model found that a minimally bridging dose in the segmental defect model was unable to overcome concomitant muscle damage, but the effect of BMP dose on composite injuries has not yet been studied. Here, we test the hypotheses that BMP-2-mediated functional regeneration of composite extremity injuries is dose dependent and can be further enhanced via co-delivery of adipose-derived microvascular fragments (MVF), which have been previously shown to increase tissue vascular volume. Although MVF did not improve healing outcomes, we observed a significant BMP-2 dose-dependent increase in regenerated bone volume and biomechanical properties. This is the first known report of an increased BMP-2 dose improving bone healing with concomitant muscle damage. While high dose BMP-2 delivery can induce heterotopic ossification (HO) and increased inflammation, the maximum 10 mg dose used in this study did not result in HO and was associated with a lower circulating inflammatory cytokine profile than the low dose (2.5 mg) group. These data support the potential benefits of an increased, though still moderate, BMP-2 dose for treatment of bone defects with concomitant muscle damage.
Composite tissue injuries present a compelling clinical challenge to both military and civilian trauma populations. Of the six million fractures that occur in the United States each year, approximately 10% are open fractures, which are characterized by concomitant soft tissue damage. These injuries experience a complication rate about twice that of closed fractures, with complications including infection, malunion, and non-union. 1 As a result, open fractures are often subject to multiple treatment strategies, repeated surgeries, and high direct and indirect costs. 2 Despite these multiple interventions, nearly twothirds of patients remain significantly disabled long term (at 7 years post-injury, and likely beyond). 3 One treatment strategy often employed in challenging bone healing scenarios is the delivery of bone morphogenetic protein-2 (BMP-2) on a collagen sponge. While most commonly used in cases of spinal fusion, 4 BMP-2 has demonstrated clinical success in long bone fracture cases for over 15 years. 5 However, BMP-2 has also been linked to side effects such heterotopic bone formation and inflammation, 6 both of which can be exacerbated by orthopedic trauma. 7 Segmental bone defect healing is known to exhibit a dose response to BMP-2 8 ; however, a minimally bridging dose for a segmental bone defect was unable to consistently bridge same-sized bone defects in a composite bone and muscle defect model. 9 Thus, the effect of BMP-2 dose is of particular interest in traumatic composite defects.
The Gustilo classification system scores open fractures from class I-IIIC in terms of increasing severity. Assignment to broad classes I-III is determined by increasing size of soft tissue loss, but the hallmark of the most severe category IIIC is vascular damageregardless of the degree of soft tissue damage. 10 The revascularization process is a rate-limiting step of the wound healing 11 and plays a crucial role in the clinical success of treatments for open fractures. Further, it is well established that angiogenesis and osteogenesis are linked 12 and that impaired revascularization impairs fracture healing in pre-clinical animal models 13 . Numerous therapeutic strategies targeting revascularization of bone have been employed, largely pre-clinically, including growth factor and cell delivery. [14] [15] [16] One promising approach is the use of microvascular fragments (MVF), multicellular segments of mature vasculature that form angiogenic networks in vitro. 17 Due to their pre-patterned tubular structure and retention of vascular support cells, MVF are attractive candidates for tissue engineering applications. 18 MVF have been shown to inosculate with host vasculature, 19, 20 increase tissue vascular volume, 20, 21 and improve tissue grafting in pre-clinical models. 22, 23 MVF are most commonly obtained from adipose tissue and therefore have potential clinical utility in an autologous application.
We have previously developed a pre-clinical small animal model of composite bone-muscle injury consisting of a critical size femoral defect with an overlying volumetric muscle loss. 9 Our model recapitulates the clinical observation of impaired bone healing when concomitant soft tissue injury is present, and this has also been seen in similar pre-clinical models of composite tissue injury. 9, [24] [25] [26] In this study, we tested the hypotheses that BMP-2-mediated functional regeneration of composite extremity injuries is dose dependent and can be further enhanced via co-delivery of adipose-derived microvascular fragments (MVF), which have been previously shown to increase tissue vascular volume.
METHODS

MVF Isolation and Construct Preparation
MVF were isolated as previously described. 17 Briefly, epididymal fat pads were harvested from two retired breeder Lewis rats to yield approximately 10-12 ml fat tissue. Fat was minced, and digested with a collagenase solution for 7 min at 37˚C. MVF were obtained through selective filtration to retain tissue between 50 and 500 mm. To prepare surgical constructs, MVF were suspended at a density of 80,000 MVF/ ml in aMEM (ThermoFisher Scientific; Waltham, MA) along with BMP-2 (Pfizer, Inc.; New York, NY) and pipetted dropwise onto collagen sponges (5 mm diameter, 1 cm height; Kensey Nash/DSM; Exton, PA).
Viability of constructs cultured in aMEM with 10% fetal bovine serum (FBS; Atlanta Biologics; Atlanta, GA) and 1% penicillin-streptomycin-L-glutamine (ThermoFisher) was evaluated using a live/dead assay kit according to manufacturer's instructions (ThermoFisher). Cylindrical constructs were cut in half lengthwise to expose the center of the sponge immediately prior to imaging. Three constructs were imaged per time point at days 1, 3, 7, 9, and 14 of culture. Viability was quantified using the ImageJ 3D objects counter to compare the number of objects in the red channel of the image versus the green channel.
Surgical Procedure
Unilateral composite defects were made in 13-week-old female Lewis rats (Charles River Laboratories; Wilmington, MA) by creating an internally stabilized 8 mm defect in the mid-diaphysis of the femur with an overlying 8 mm diameter full-thickness quadriceps defect as previously described. 9 Collagen sponges (5 mm diameter, 1 cm height) loaded with BMP-2 AE MVF were press fit into the defect. Sponges contained 2.5 mg BMP-2 without MVF (n ¼ 8 animals), 2.5 mg BMP-2 with MVF (n ¼ 8), 10 mg BMP-2 without MVF (n ¼ 9), or 10 mg BMP-2 with MVF (n ¼ 10). Animal number was determined from previous studies of segmental bone defect healing, and animals were randomly assigned to treatment groups. Animals were double-housed, maintained on a 12-h light/dark cycle, and allowed ad libitum access to food and water. At 12-week post-surgery, animals were euthanized by CO 2 inhalation. All animal experiments were performed in accordance with the Georgia Institute of Technology Institutional Animal Care and Use Committee (IACUC).
Bone Regeneration Analyses
Bone healing was qualitatively assessed by radiography at 2, 4, 8, and 12 weeks post-surgery and quantitatively assessed by micro-computed tomography (mCT) at 4, 8, and 12 weeks post-surgery. The defect region was scanned with a voxel size of 38.9 mm. The middle 6.5 mm of the defect was analyzed, and bone volume was quantified by Scanco software using a threshold corresponding to 50% of intact cortical bone. 8, 9 Polar moment of inertia was calculated for each mCT slice as a measure of the distribution of bone relative to the central axis using a Scanco evaluation script. 27 An average of all slices' polar moment of inertia was calculated to determine a global value for each sample. 28 Mechanical testing and histology were performed at the 12-week endpoint after euthanasia. Thighs were harvested, soft tissue was cleared, and fixation plates were removed. Femur ends were potted in Wood's metal (Alfa Aesar) and tested in torsion at a rate of 3˚/s to failure (ELF 3200, TA ElectroForce). 29 Maximum torque (torque at failure) and torsional stiffness (linear region of torque vs. rotation) were calculated for all samples.
Following mechanical testing, one sample from each group was fixed in 10% neutral buffered formalin (NBF) for 24 h and decalcified in a formic citrate solution (Newcomer Supply, Inc; Middleton, WI). Bone and muscle tissues were embedded in paraffin and sectioned at a thickness of 5 mm. Bone tissue was stained with hematoxylin and eosin (H&E); muscle tissue was stained with H&E and with Masson's Trichrome to observe fibrosis (Histotox Labs; Boulder, CO). Bone sections were also stained with rhodamine-labeled Griffonia simplicifolia lectin I (GS-1 lectin; Vector Laboratories; Burlingame, CA) at a concentration of 10 mg/ml and counterstained with DAPI (ThermoFisher) diluted 1:1,000 in phosphate buffered saline to identify blood vessels.
Serum Cytokine Quantification
At the week 12 endpoint, blood was collected via the rat tail vein from a subset of animals from each treatment group (n ¼ 5/group). Serum was collected from whole blood for multiplexed analyte analysis for 27 inflammatory cytokines and chemokines. Samples were prepared using a multiplexed rat cytokine/chemokine magnetic bead panel (MILLIPLEX RECYTMAG-65K), according to manufacturer's instructions. Data were collected using a MAGPIX multiplexing system (Luminex Corporation; Austin, TX).
Statistical Analysis
Data were analyzed using GraphPad Prism 7 and are represented as mean AE standard error of the mean (SEM). Bone volume, maximum torque, torsional stiffness, and cytokine levels were analyzed by two-way analysis of variance (ANOVA) and Bonferroni post hoc tests with an alpha level of 0.05.
RESULTS
Construct Viability MVF cultured in BMP-2 loaded collagen sponges maintained viability in vitro throughout the threedimensional construct (Fig. 1) . However, multicellular MVF appeared to dissociate to single cells by day 3 of culture and reform networks by day 9-14. Approximately 65% of the cells were viable at day 3; over 90% of cells were viable at days 7-14. 
Bone Regeneration
Radiography and mCT Radiographs demonstrated that a majority of defects bridged in all four treatment groups (Fig. 2) . By 12 weeks, all defects treated with 10 mg BMP-2, with and without MVF, had bridged (9 of 9 and 10 of 10, respectively). Seven of eight defects treated with 2.5 mg BMP-2 without MVF bridged, and five of eight defects treated with 2.5 mg BMP-2 with MVF bridged. Bone volume in the defect region was measured by mCT and was significantly higher in the 10 mg dose groups than in the 2.5 mg dose groups ( Fig. 3A; overall effect, p ¼ 0.0312). There was no effect of the MVF treatment on bone volume and no significant interaction. The polar moment of inertia was also calculated as a measure of the distribution of bone relative to the central axis. pMOI was significantly lower in the 2.5 mg dose groups ( Fig. 3B ; overall effect, p ¼ 0.0047). This corresponds to the more compact morphology observed in the radiographs (Fig. 2) and mCT reconstructions of the 2.5 mg dose groups (Fig. 3C) . Bone density was approximately 870 mm hydroxyapatite/ cm 3 for all four groups.
Mechanics
The torque to failure was significantly higher for the 10 mg dose BMP-2 groups than the 2.5 mg dose groups ( Fig. 4 ; post hoc, p < 0.001). There was no effect of MVF and no significant interaction. Despite the increased strength of the 10 mg BMP-2 treatment, the 10 mg dose without MVF group still only achieved 60.5% of intact strength. Stiffness was also significantly higher in the 10 mg dose groups than in the 2.5 mg dose groups (overall effect, p ¼ 0.0005), and stiffness was significantly decreased in groups with MVF compared to without MVF (overall effect, p ¼ 0.0098).
Histology
Qualitative histological assessment of bone defects supported the quantitative mCT data. The 10 mg dose without MVF group showed the greatest amount of bone organized in apparent lamellae, and both groups that received MVF showed larger areas of non-mineralized, marrow-like tissue (Fig. 5 ). There were no qualitative differences in relative number of lectinstained blood vessel structures among treatment groups at the 12-week time point (Fig. 6 ). As expected, the untreated muscle defects did not heal over the course of this study. At the 12-week end point, muscle exhibited a large degree of fibrosis and fatty infiltration (Fig. 7) . No qualitative differences in muscle healing were apparent between the well healing 10 mg BMP-2 without MVF and poorly healing 2.5 mg BMP-2 with MVF groups.
Serum Cytokine Quantification
Blood was collected at the 12-week end point to quantify systemic levels of circulating inflammatory cytokines (n ¼ 5/group). Levels of multiple interleukins (IL) were significantly decreased in blood samples taken from animals treated with the increased 10 mg BMP-2 dose groups, both with and without MVF (Fig. 8) . Both pro-inflammatory interleukins, such as IL-1a and IL-1b, and anti-inflammatory interleukins, such as IL-5, IL-10, and IL-13, 30 were decreased in the 10 mg BMP-2 dose groups Pro-inflammatory eotaxin was also lower (p ¼ 0.0507) in the 10 mg BMP dose groups.
DISCUSSION
Composite tissue extremity injuries represent a significant challenge to orthopedic surgeons and a momentous hardship for patients. Vascularization is an enabling step of wound healing, and we hypothesized that BMP-2-mediated functional regeneration of composite extremity injuries would be dose dependent and could be further enhanced via co-delivery of adiposederived microvascular fragments (MVF), which have been previously shown to increase tissue vascular volume.
BMP-2 is clinically approved for a number of bone healing indications and has shown success in treating long bone fractures and non-unions. 5, 31 There is a BMP-2 dose response in humans and in pre-clinical animal models, but precise dosing required for specific human applications is not well defined. 8, 31 High BMP-2 dosage has been linked a number of side effects including heterotopic ossification (HO) and increased inflammation, 6 and HO is also often increased in cases of trauma. [32] [33] [34] While a 2.5 mg dose of BMP-2 is a bridging dose in a segmental defect model, 8 it produces inconsistent bridging in this challenging composite defect model. 9 In this segmental defect model, HO has been observed at 30 mg doses of BMP-2.
28, 35 We showed in the present study that a 10 mg dose is sufficient to improve composite defect healing relative to the 2.5 mg dose and does not lead to mineralization outside the collagen sponge delivery vehicle. A moderately increased dose (e.g., 10 mg relative to 2.5 or 30 mg) may be required in composite injuries to compensate for the loss of endogenous stem and progenitor cells and growth factor availability as a result of the concomitant muscle loss. When scaled by body surface area (assuming a 60 kg human relative to a 0.25 kg rat), a 2.5 mg rat dose would be equivalent to 0.114 mg in humans, and a 10 mg dose would be equivalent to 0.454 mg. 36 This is lower than the current FDA approved dose of BMP-2 for tibial fractures of 12 mg. 5 However, there is known species variation for BMP-2 dose specifically, with sheep requiring higher doses than rodents and non-human 
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primates requiring higher doses still. 37 Together, these studies demonstrate the need for precise identification of the appropriate clinical dosing window of BMP-2. While muscle loss constitutes an increased level of trauma, this model does not incorporate head trauma or muscle crush, which are known contributors to human post-traumatic HO. 33, 34 Traumatically injured muscle can give rise to osteogenic progenitor cells, 34 but it is unknown whether a similar effect would be present in this model which cleanly removes a volumetric section of muscle with a biopsy punch. While large volume muscle loss has been shown to have a more profound impact on bone healing than muscle crush injuries, 38 the VML model utilized here may not fully recapitulate the HO risk associated with trauma of clinical open fractures that often also have significant muscle damage. Future work may be warranted to investigate more aggressive debridement of damaged muscle adjacent to bone injuries as prophylaxis for HO, though this could potentially lead to reduced functional outcomes.
Local healing at the site of a regenerative intervention, as well as HO, are both thought to be influenced by the systemic immune response. Interestingly, the Figure 8 . Relative serum levels of pro-(top) and anti-inflammatory (bottom) cytokines by treatment group as measured by multiplexed analyte analysis.
Ã Post hoc differences due to BMP dose, p < 0.05; two-way ANOVA; n ¼ 5/group. 558 RUEHLE ET AL.
10 mg BMP dose resulted in lower levels of both proand anti-inflammatory systemic cytokines relative to the 2.5 mg dose at the 12-week time point. The 2.5 mg dose group's failure to completely heal may have prolonged the inflammatory stage of the wound healing process, which previous studies have shown to be increased in composite tissue injuries. 24 That persistent local inflammation may then have resulted in altered systemic immune cytokine profiles. Rather than a high BMP dose inducing inflammation, the successful bridging and restoration of function may have resolved the local inflammation and led to lower cytokine levels by the 12-week time point. Future studies investigating inflammatory profiles at earlier time points would be required to more definitively address the composite injury's inflammatory response to various BMP doses.
MVF were used as a proposed therapeutic approach to enhance revascularization and subsequently bone regeneration; however, the MVF treatment did not improve bone volume or failure strength and in fact decreased the stiffness of the regenerated bone. Although MVF treatment had no significant effect on bone volume, the mineralization pattern of the regenerated bone appeared more fragmented in MVFtreated defects as observed with mCT. The fragmented mineralization of MVF-treated groups may have contributed to the differences in mechanical properties. MVF have been shown to improve tissue vascularization and integration; however, this has been primarily demonstrated in subcutaneous implantation, 20 skin flaps, 39 and dermal substitutes, 22, 23 all of which are considerably thinner and thus closer to native vascular sources than the critical size bone defect used here. MVF have also been shown to increase tissue perfusion in VML models when delivered in collagen gel, 21, 40 which allows for sprouting angiogenesis. 17, 21, 41, 42 In this study, while in vitro viability of MVF was maintained in collagen sponge, the multicellular MVF first dissociated to single cells and then reformed networks. This is not consistent with the sprouting angiogenesis typically observed within a collagen gel and may have contributed to the lack of effect of MVF on bone healing. While collagen sponge is a clinically available BMP-2 delivery vehicle, it may not be an optimal delivery vehicle for MVF, which are exquisitely sensitive to extracellular matrix properties. 41, 43 Further, MVF exert traction forces on their matrices and can contract collagen hydrogels 17, 42, 44 ; cell-mediated contraction of collagen sponge may have contributed to the more fragmented mineralization observed in the MVF-treated defects (Fig. 3C) .
Beyond the vascular components of adipose-derived MVF, these structures also contain mesenchymal stem cells (MSCs). 23, 45 Exogenously delivered adipose-derived MSCs have previously been shown to negatively affect mineralization when co-delivered with BMP-2.
differentially interact with BMP-2 to dampen or alter its signaling to endogenous host cells. However, adipose-derived MVF contain only about 2-7% MSCs, 23, 47 so their relative contribution may be proportionally small. Retention of other adipose-derived cells may have contributed to the larger marrow spaces histologically observed in MVF-treated defects (Fig. 5) , and adipose-derived MVF may not be suitable for bone defect applications.
Delivery of MVF also did not result in qualitative differences in lectin-stained blood vessel structures at 12 weeks. Cell implantation strategies broadly are challenged by issues of viability and retention. [48] [49] [50] Although vascularization is hypothesized to improve viability by enabling nutrient and oxygen transport, the implanted MVF may have failed to survive long enough to inosculate with the host vasculatureparticularly due to their dissociation within the collagen sponge. Future studies to assess MVF retention, viability, and vascularization at earlier time points are required.
This is the first investigation of BMP-2 dose in a composite defect model. While the delivery of MVF did not improve bone healing in the composite defect model, an increased dose of 10 mg BMP-2 significantly improved bone healing and regenerate bone mechanics relative to a 2.5 mg dose. While 2.5 mg BMP-2 restored bone failure strength to only 20% of intact strength, a 10 mg BMP dose restored failure strength to 60% of intact. This improvement may represent significant functional improvements but also underscores the challenging nature of healing composite tissue injuries. Collagen sponge is a clinically approved, and therefore translationally relevant, BMP-2 delivery vehicle but may not be an appropriate MVF delivery vehicle. A modest increase in BMP-2 dosage may be a clinically relevant treatment strategy for critical size bone defects with concomitant muscle damage while a biomaterial delivery system for co-delivery of MVF is developed. Approaches that enhance early vascularization may be required to restore regenerated bone to greater than 60% of intact strength in cases of composite bone and muscle traumatic injury. 
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